Pt3 4 Cn0m0 Melanoma clinical trials

Explore recruiting pt3 4 cn0m0 melanoma clinical trials.

Also recruiting in Europe

Pt3 4 Cn0m0 Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in clinical cT3-4N0M0 Melanoma (Intrim 1 study)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Pt3 4 Cn0m0 Melanoma trials by city

Pt3 4 Cn0m0 Melanoma in Toronto Pt3 4 Cn0m0 Melanoma in Vancouver Pt3 4 Cn0m0 Melanoma in Montreal Pt3 4 Cn0m0 Melanoma in Calgary Pt3 4 Cn0m0 Melanoma in Edmonton Pt3 4 Cn0m0 Melanoma in Ottawa Pt3 4 Cn0m0 Melanoma in Winnipeg Pt3 4 Cn0m0 Melanoma in Quebec City Pt3 4 Cn0m0 Melanoma in Hamilton Pt3 4 Cn0m0 Melanoma in Kitchener Pt3 4 Cn0m0 Melanoma in London Pt3 4 Cn0m0 Melanoma in Halifax Pt3 4 Cn0m0 Melanoma in New York Pt3 4 Cn0m0 Melanoma in Los Angeles Pt3 4 Cn0m0 Melanoma in Chicago Pt3 4 Cn0m0 Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease